The Great Healthcare Plan

The Great Healthcare Plan proposed by President Trump seeks to lower prescription drug prices (including codifying Most-Favored-Nation deals and expanding OTC availability), redirect insurer subsidy payments directly to individuals, fund a cost‑sharing reduction program estimated by the CBO to save taxpayers at least $36 billion and reduce common Obamacare plan premiums by over 10%, and eliminate PBM kickbacks. The proposal also mandates insurer transparency (publish payout ratios, claim denial rates and wait times) and requires Medicare/Medicaid providers to post prices, creating meaningful regulatory and revenue risk for drugmakers, insurers and PBMs if enacted.

Analysis

Market structure: Codifying Most-Favored-Nation pricing and banning PBM kickbacks reallocates margin from branded pharma and integrated PBM-insurers toward generics, OTC and transparent retailers. Expect branded pharma EBIT compression of 5–15% in a stress case over 12–36 months; generics/OTC players could see 5–10% revenue upside as more drugs move OTC and volume shifts. Insurers face mixed effects: lower premiums reduce revenue per enrollee but transparency rules raise reputational risk and could compress medical loss ratios.

Risk assessment: Near-term (days–weeks) headline risk centers on legislative traction and lobbying; medium-term (3–12 months) regulatory rulemaking and lawsuits are likely tail events that could delay impact. Low-probability high-impact outcomes include broad price caps or cross-border reference pricing that cut branded revenues 20%+ and trigger R&D pullback, or court blocks that preserve status quo. Hidden dependencies: grandfathering of voluntary deals and trade/IP challenges could blunt immediate effects.

Trade implications: Tactical alpha will come from relative value, not blanket longs/shorts. Short selected large-cap innovators and integrated PBM/insurers if legislative text gains traction in 30–90 days; rotate into generics, OTC manufacturers and retail pharmacies that compete on volume and transparent pricing. Use options to time-event risk around committee votes and CBO cost estimates to limit left-tail exposures.

Contrarian angle: Consensus treats all pharma as uniformly negative; the mispricing is in differentiated exposure — mature small-molecule franchises with easy international reference comparators are most at risk, while patented biologics and specialty injectables with limited substitutes are more insulated. Historical parallels: 2014–2015 Medicare negotiation scares created 10–20% selloffs that reversed when scope narrowed; if legislation is watered down the transitory selloff will create buying opportunities.

Key Decisions for Investors

• Establish a 1.5% portfolio short via 6-month put spreads (buy 25-delta, sell 10-delta) on Pfizer (PFE) and Merck (MRK) combined (0.75% each). Rationale: targeted downside if MFN-like pricing gains traction; close or cut if bill fails to reach committee within 90 days or if CBO impact <3%.
• Build a 2–3% long allocation in generics/OTC: 60% TEVA (TEVA) and 40% Viatris (VTRS) equities. Add a staggered 9-month call-spread overlay (buy 30-delta / sell 15-delta) sized at 25% of equity position to lever upside if OTC conversions accelerate >5% volume growth over 12 months.
• Initiate a 1% pair trade long Walgreens Boots Alliance (WBA) and short CVS Health (CVS) 1:1 notional. Thesis: WBA benefits from OTC sales without PBM exposure; CVS bears PBM/insurer policy execution risk. Use 6–12 month horizon and place stop-loss at 20% adverse move.
• Purchase a defensive hedge: 6-month put spread on UnitedHealth (UNH) sized to 0.5% portfolio (buy 25-delta / sell 10-delta) to protect against systemic insurer multiple compression if transparency rules materially widen loss ratios. Scale up if CBO scores potential taxpayer cost/shifts >$20bn within 60 days.